|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||
  British Journal of Clinical PharmacologyVolume 46 Issue 2, Pages 173 - 175 Published Online: 4 Jan 2002 Journal compilation © 2010 The British Pharmacological Society The Journal of The British Pharmacological Society
Abstract | References | Full Text: HTML, PDF (Size: 75K) | Related Articles | Citation Tracking  Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration Copyright 1998 Blackwell Science Ltd KEYWORDS delayed-release mesalazine • omeprazole • lactulose • pH-dependent drug delivery • ulcerative colitis ABSTRACTAims Delayed-release formulations of mesalazine often rely on the gastrointestinal luminal pH profile to deliver 5-aminosalicylic acid (5ASA) to the colon. The aim of this study was to examine the influence of luminal pH on mesalazine release. Methods We studied the effect of co-administration of omeprazole and lactulose on the steady-state pharmacokinetics of Eudragit S-coated mesalazine in healthy volunteers. Results No significant changes in urinary or faecal levels of 5ASA or its main metabolite, N-acetyl 5ASA, were apparent. Conclusions This study suggests that co-administration of omeprazole and lactulose does not impair the release of delayed-release mesalazine.
| 
|
